Using a database of HIV patients undergoing genotypic resistance test after HAART failure to understand the dynamics of M184V mutation

Mauro Zaccarelli, Carlo Federico Perno, Federica Forbici, Antonella Cingolani, Guiseppina Liuzzi, Ada Bertoli, Maria Paola Trotta, Maria Concetta Bellocchi, Simona Di Giambenedetto, Valerio Tozzi, Caterina Gori, Roberta D'Arrigo, Patrizio De Longis, Pasquale Noto, Enrico Girardi, Andrea De Luca, Andrea Antinori

Research output: Contribution to journalArticle

Abstract

Objective: M184V/I mutation is associated with high-level phenotypic resistance to lamivudine (3TC). The aim of the present analysis was to correlate the time of appearance/disappearance of M184V/I with duration of 3TC treatment. Methods: Overall, 211 patients were selected from a database of HIV patients undergoing genotypic resistance test after virological failure of HAART regimens in two major reference centres in Rome between 1999 and 2001. At the time of genotyping, 120 of them (56.9%) were failing a 3TC-including HAART, while 91 (43.1%) received 3TC only in previous HAART. Duration of the current 3TC-containing regimen and the time from the end of last 3TC treatment to genotypic resistance test (GRT) were analysed. Results: Among patients currently undergoing 3TC-containing HAART, the prevalence of M184V/I was 82.5% (78.3/4.2%, respectively) and significantly associated to current 3TC use at GRT. Prevalence of M184V/I was associated to longer history of 3TC (from 47.1% in patients treated with 3TC for 42 months of current 3TC carried M184V. At logistic regression analysis, the rate of increase of M184V/I in 3TC-failing patients was statistically significant (OR: 1.066 per month of current 3TC therapy, 95% CI: 1.020-1.114, P

Original languageEnglish
Pages (from-to)51-56
Number of pages6
JournalAntiviral Therapy
Volume8
Issue number1
Publication statusPublished - Feb 2003

Fingerprint

Lamivudine
Highly Active Antiretroviral Therapy
HIV
Databases
Mutation

ASJC Scopus subject areas

  • Pharmacology

Cite this

Using a database of HIV patients undergoing genotypic resistance test after HAART failure to understand the dynamics of M184V mutation. / Zaccarelli, Mauro; Perno, Carlo Federico; Forbici, Federica; Cingolani, Antonella; Liuzzi, Guiseppina; Bertoli, Ada; Trotta, Maria Paola; Bellocchi, Maria Concetta; Di Giambenedetto, Simona; Tozzi, Valerio; Gori, Caterina; D'Arrigo, Roberta; De Longis, Patrizio; Noto, Pasquale; Girardi, Enrico; De Luca, Andrea; Antinori, Andrea.

In: Antiviral Therapy, Vol. 8, No. 1, 02.2003, p. 51-56.

Research output: Contribution to journalArticle

Zaccarelli, Mauro ; Perno, Carlo Federico ; Forbici, Federica ; Cingolani, Antonella ; Liuzzi, Guiseppina ; Bertoli, Ada ; Trotta, Maria Paola ; Bellocchi, Maria Concetta ; Di Giambenedetto, Simona ; Tozzi, Valerio ; Gori, Caterina ; D'Arrigo, Roberta ; De Longis, Patrizio ; Noto, Pasquale ; Girardi, Enrico ; De Luca, Andrea ; Antinori, Andrea. / Using a database of HIV patients undergoing genotypic resistance test after HAART failure to understand the dynamics of M184V mutation. In: Antiviral Therapy. 2003 ; Vol. 8, No. 1. pp. 51-56.
@article{d392bfd8d99643ce9116858dbf5e4579,
title = "Using a database of HIV patients undergoing genotypic resistance test after HAART failure to understand the dynamics of M184V mutation",
abstract = "Objective: M184V/I mutation is associated with high-level phenotypic resistance to lamivudine (3TC). The aim of the present analysis was to correlate the time of appearance/disappearance of M184V/I with duration of 3TC treatment. Methods: Overall, 211 patients were selected from a database of HIV patients undergoing genotypic resistance test after virological failure of HAART regimens in two major reference centres in Rome between 1999 and 2001. At the time of genotyping, 120 of them (56.9{\%}) were failing a 3TC-including HAART, while 91 (43.1{\%}) received 3TC only in previous HAART. Duration of the current 3TC-containing regimen and the time from the end of last 3TC treatment to genotypic resistance test (GRT) were analysed. Results: Among patients currently undergoing 3TC-containing HAART, the prevalence of M184V/I was 82.5{\%} (78.3/4.2{\%}, respectively) and significantly associated to current 3TC use at GRT. Prevalence of M184V/I was associated to longer history of 3TC (from 47.1{\%} in patients treated with 3TC for 42 months of current 3TC carried M184V. At logistic regression analysis, the rate of increase of M184V/I in 3TC-failing patients was statistically significant (OR: 1.066 per month of current 3TC therapy, 95{\%} CI: 1.020-1.114, P",
author = "Mauro Zaccarelli and Perno, {Carlo Federico} and Federica Forbici and Antonella Cingolani and Guiseppina Liuzzi and Ada Bertoli and Trotta, {Maria Paola} and Bellocchi, {Maria Concetta} and {Di Giambenedetto}, Simona and Valerio Tozzi and Caterina Gori and Roberta D'Arrigo and {De Longis}, Patrizio and Pasquale Noto and Enrico Girardi and {De Luca}, Andrea and Andrea Antinori",
year = "2003",
month = "2",
language = "English",
volume = "8",
pages = "51--56",
journal = "Antiviral Therapy",
issn = "1359-6535",
publisher = "International Medical Press Ltd",
number = "1",

}

TY - JOUR

T1 - Using a database of HIV patients undergoing genotypic resistance test after HAART failure to understand the dynamics of M184V mutation

AU - Zaccarelli, Mauro

AU - Perno, Carlo Federico

AU - Forbici, Federica

AU - Cingolani, Antonella

AU - Liuzzi, Guiseppina

AU - Bertoli, Ada

AU - Trotta, Maria Paola

AU - Bellocchi, Maria Concetta

AU - Di Giambenedetto, Simona

AU - Tozzi, Valerio

AU - Gori, Caterina

AU - D'Arrigo, Roberta

AU - De Longis, Patrizio

AU - Noto, Pasquale

AU - Girardi, Enrico

AU - De Luca, Andrea

AU - Antinori, Andrea

PY - 2003/2

Y1 - 2003/2

N2 - Objective: M184V/I mutation is associated with high-level phenotypic resistance to lamivudine (3TC). The aim of the present analysis was to correlate the time of appearance/disappearance of M184V/I with duration of 3TC treatment. Methods: Overall, 211 patients were selected from a database of HIV patients undergoing genotypic resistance test after virological failure of HAART regimens in two major reference centres in Rome between 1999 and 2001. At the time of genotyping, 120 of them (56.9%) were failing a 3TC-including HAART, while 91 (43.1%) received 3TC only in previous HAART. Duration of the current 3TC-containing regimen and the time from the end of last 3TC treatment to genotypic resistance test (GRT) were analysed. Results: Among patients currently undergoing 3TC-containing HAART, the prevalence of M184V/I was 82.5% (78.3/4.2%, respectively) and significantly associated to current 3TC use at GRT. Prevalence of M184V/I was associated to longer history of 3TC (from 47.1% in patients treated with 3TC for 42 months of current 3TC carried M184V. At logistic regression analysis, the rate of increase of M184V/I in 3TC-failing patients was statistically significant (OR: 1.066 per month of current 3TC therapy, 95% CI: 1.020-1.114, P

AB - Objective: M184V/I mutation is associated with high-level phenotypic resistance to lamivudine (3TC). The aim of the present analysis was to correlate the time of appearance/disappearance of M184V/I with duration of 3TC treatment. Methods: Overall, 211 patients were selected from a database of HIV patients undergoing genotypic resistance test after virological failure of HAART regimens in two major reference centres in Rome between 1999 and 2001. At the time of genotyping, 120 of them (56.9%) were failing a 3TC-including HAART, while 91 (43.1%) received 3TC only in previous HAART. Duration of the current 3TC-containing regimen and the time from the end of last 3TC treatment to genotypic resistance test (GRT) were analysed. Results: Among patients currently undergoing 3TC-containing HAART, the prevalence of M184V/I was 82.5% (78.3/4.2%, respectively) and significantly associated to current 3TC use at GRT. Prevalence of M184V/I was associated to longer history of 3TC (from 47.1% in patients treated with 3TC for 42 months of current 3TC carried M184V. At logistic regression analysis, the rate of increase of M184V/I in 3TC-failing patients was statistically significant (OR: 1.066 per month of current 3TC therapy, 95% CI: 1.020-1.114, P

UR - http://www.scopus.com/inward/record.url?scp=12244282436&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12244282436&partnerID=8YFLogxK

M3 - Article

C2 - 12713064

AN - SCOPUS:12244282436

VL - 8

SP - 51

EP - 56

JO - Antiviral Therapy

JF - Antiviral Therapy

SN - 1359-6535

IS - 1

ER -